Cancer Facts & Figures 2013

Special Section: Pancreatic Cancer

Cancer of the pancreas is one of the deadliest cancer types. Most pancreatic cancer patients will die within the first year of diagnosis, and just 6% will survive five years. Over the past decade, pancreatic cancer death rates have been slowly increasing among US men and women, in contrast to the downward trend in rates for most other major cancer sites, such as lung, colorectum, female breast, and prostate. The lack of progress in primary prevention, early diagnosis, and treatment underscores the need for additional efforts in pancreatic cancer research and has motivated us to address this disease in the current edition of Cancer Facts & Figures. Specifically, this special section provides updated information on occurrence, prevention, early detection, diagnosis, and treatment of pancreatic cancer. This information is intended to inform anyone interested in learning more about pancreatic cancer, including policy makers, researchers, clinicians, cancer control advocates, patients, and caregivers.

The pancreas contains two types of glands that each perform very different functions. The exocrine glands produce enzymes that help digest food; the endocrine glands produce important hormones such as insulin, which regulates blood sugar levels. Exocrine and endocrine cells form completely different types of tumors with distinct risk factors, symptoms, diagnostic tests, treatment, and survival rates. Exocrine tumors are the focus of this special section because they are by far the most common type of pancreatic cancer, representing about 95% of cases.

How Many Cases and Deaths Are Estimated to Occur in 2013?

Pancreatic cancer is the 10th most common cancer diagnosis among men and the 9th most common among women in the US. In 2013, an estimated 45,220 new cases of pancreatic cancer will be diagnosed nationwide.

Pancreatic cancer accounts for about 7% of all cancer deaths and ranks fourth as a cause of cancer death among both men and women in the US. In 2013, approximately 38,460 people are expected to die from pancreatic cancer nationwide.

Who Gets Pancreatic Cancer?

Sex

- Men are more likely than women to develop pancreatic cancer at every age after 35 years (Figure 1a, page 26).
- During 2005-2009, the age-adjusted death rate (per 100,000 persons) for pancreatic cancer was 12.5 for men and 9.5 for women.

Age

- Pancreatic cancer incidence and death rates increase with advancing age, with a steep increase after about age 50.
- During 2005-2009, the incidence rate (per 100,000) in men was 1.2 among those 35 to 39 years of age compared to 100.5 among those 85 years and older; in women the rate was 1.0 among those 35 to 39 years of age compared to 87.7 among those 85 years and older (Figure 1a, page 26).
- During 2005-2009, the median age at diagnosis of pancreatic cancer was 71 years of age. This means that about half of all patients developed this disease when they were older than age 71.
- The likelihood of developing pancreatic cancer in the next 10 years is about four times higher at age 70 than at age 50 (Table 1).

Race/Ethnicity

- Pancreatic cancer incidence and mortality rates vary across different racial/ethnic groups, with the highest rates in African Americans and the lowest rates in Asian Americans/Pacific Islanders (Figure 2, page 27).
- Incidence rates are higher in African Americans than in whites at every age (Figure 1b, page 26).
- During 2005-2009, the incidence rate (per 100,000 persons) was 15.3 for African Americans, 11.6 for whites, and 8.8 for Asian Americans/Pacific Islanders.

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 39</td>
<td>0.01 (1 in 9,746)</td>
<td>0.01 (1 in 9,479)</td>
</tr>
<tr>
<td>40-49</td>
<td>0.05 (1 in 2,063)</td>
<td>0.04 (1 in 2,674)</td>
</tr>
<tr>
<td>50-59</td>
<td>0.18 (1 in 563)</td>
<td>0.12 (1 in 843)</td>
</tr>
<tr>
<td>60-69</td>
<td>0.41 (1 in 241)</td>
<td>0.30 (1 in 335)</td>
</tr>
<tr>
<td>70-79</td>
<td>0.65 (1 in 155)</td>
<td>0.56 (1 in 179)</td>
</tr>
<tr>
<td>Lifetime risk</td>
<td>1.48 (1 in 67)</td>
<td>1.45 (1 in 69)</td>
</tr>
</tbody>
</table>

*For people free of cancer at beginning of age interval. Percentages and “1 in” numbers may not be equivalent due to rounding.

- Mortality rates (per 100,000 persons) during the corresponding time interval were 13.8, 10.7, and 7.5 for African Americans, whites, and Asian American/Pacific Islanders, respectively.
- Racial differences in pancreatic cancer rates are largely explained by established risk factors, such as cigarette smoking, obesity, and diabetes.¹

**Socioeconomic status**

Number of years of education is one measure of socioeconomic status used by researchers to study health disparities.

- Pancreatic cancer death rates are higher among those with fewer years of education.
- One study found that in 2007, the pancreatic cancer death rate among non-Hispanic white men 25 to 64 years of age was about 80% higher for those with 12 or fewer years of education than for those with 16 or more years of education; among non-Hispanic white women, the death rate for the less-educated group was double that of the most educated.²
- This study also found that from 1993 to 2007, pancreatic cancer death rates among non-Hispanic white men and women 25 to 64 years of age increased among those with the least education, but remained stable among those with the most education.²
- Another study found that low income was associated with an 80% increased risk of pancreatic cancer in white men and a 170% increased risk in African American men after accounting for differences in smoking, dietary factors, and heavy alcohol drinking.³

**Are There Geographic Differences in Pancreatic Cancer in the US?**

- Despite substantial international variation, within the US, pancreatic cancer incidence and mortality rates vary only slightly between states.
- Among whites, pancreatic cancer death rates are highest in the Northeast, and range from 8.4 (per 100,000) in the District of Columbia to 12.1 in Connecticut (Figure 3, page 28).
- Among African Americans, death rates are highest in the Midwest, and range from 7.8 (per 100,000) in West Virginia to 18.9 in Iowa (Figure 3, page 28).

**How Has the Occurrence of Pancreatic Cancer Changed over Time?**

**Incidence trends**

During the past 10 years of data (2000-2009), for which we have coverage for almost the entire US, pancreatic cancer incidence rates increased by 0.9% per year among white men, white women, and African American men, while rates remained stable for African American women and men and women of all other major racial and ethnic groups.³

**Mortality trends**

Although the pancreatic cancer death rate increased for the overall US over the past 10 years of data (2000-2009), this increase was confined to white men and women (by 0.5% per year) and Asian American and Pacific Islander men (by 1.0% per year).³
Can Pancreatic Cancer Be Prevented?

The causes of pancreatic cancer are not well understood, though there are several factors known to increase risk. Known modifiable risk factors include obesity, cigarette smoking, and other forms of tobacco use. Risk factors that are not modifiable include a family history of pancreatic cancer and certain inherited syndromes. Strategies for preventing pancreatic cancer include not smoking and maintaining normal body weight. Consuming adequate quantities of fruits and vegetables may also have a preventive effect, although strong evidence for this association is lacking.

**Modifiable Risk Factors**

**Tobacco use**

Tobacco use is the most important known risk factor for pancreatic cancer; approximately 20% of pancreatic cancers are attributable to cigarette smoking.1 The risk of developing pancreatic cancer is about twice as high among smokers as among never smokers;5 risk increases with greater tobacco use and longer duration of smoking.5,6 Cigar and pipe smoking also increase risk.6,7 Quitting smoking rapidly reduces the risk of pancreatic cancer; after 5-10 years of cessation, the risk among former smokers returns to that of never smokers.6,8 Use of smokeless tobacco products also increases the risk of pancreatic cancer.11 Evidence on secondhand smoke exposure and pancreatic cancer is inconsistent.12

**Obesity and physical activity**

Obesity has also been fairly consistently linked to increased risk of pancreatic cancer. Obese individuals have a 20% higher risk of developing pancreatic cancer than those who are normal weight.11-12 Being obese during early adulthood may be associated with an even greater risk of pancreatic cancer and a younger age of disease onset.16 Abdominal obesity may increase risk independent of general obesity, especially in women.15,17

Results regarding the association between physical activity and pancreatic cancer risk are mixed.14,16,21 A slightly decreased risk of pancreatic cancer was linked to total and occupational physical activity in a recent literature review22 but not in a previous one.23 There is currently limited evidence to support a protective effect of recreational physical activity on risk of pancreatic cancer.22

**Alcohol use**

Whether alcohol use causes pancreatic cancer remains to be determined. A positive association between alcohol use and pancreatic cancer was found in several but not all studies.24 Accumulating evidence suggests that a moderate increased risk is limited to heavy alcohol users.25 A recent meta-analysis showed that consumption of three or more drinks of alcohol per day is associated with a 20% to 30% increased risk of pancreatic cancer.25 However, due to the strong relationship between alcohol consumption and tobacco use, it is difficult to eliminate the effect of smoking when studying the association between alcohol drinking and pancreatic cancer risk.

**Dietary factors**

A number of dietary factors have been assessed regarding their association with pancreatic cancer risk. There is some evidence that the consumption of red and processed meat may slightly increase risk.26 Investigators have also found some evidence for increased risk among those who consume meat that has been cooked at very high temperatures.27 A protective effect of folate intake on pancreatic cancer risk has been reported in several studies;28 however, a recent large analysis found no association.29 At present, there is limited evidence supporting a protective effect of fruit and vegetable consumption on the risk of pancreatic cancer.30-33 No association between coffee consumption and pancreatic cancer was found in a recent analysis that combined many studies.34

**Sunlight and vitamin D**

Studies are conflicting about the relationship between sunlight, vitamin D, and pancreatic cancer. Several studies have found that sun exposure is associated with lower pancreatic cancer death rates, suggesting that vitamin D, acquired primarily through sun exposure to the skin, may be protective against pancreatic cancer.35-37 However, results from epidemiological studies that assessed individual-level vitamin D intake and pancreatic cancer risk have been inconsistent. Two large studies found that both dietary vitamin D and vitamin D derived from both diet and sunlight exposure are protective.38,39 Conversely, a recently published analysis found that while there was no association between low levels of vitamin D and pancreatic cancer, high vitamin D levels were associated with an increased risk of pancreatic cancer.40

---

**Figure 2. Pancreatic Cancer Incidence and Mortality Rates* by Race and Ethnicity†, US, 2005-2009.**

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>African American</td>
<td>15.2</td>
<td>7.5</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>11.7</td>
<td>8.8</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>10.9</td>
<td>8.8</td>
</tr>
<tr>
<td>American Indians/Alaska Native</td>
<td>8.3</td>
<td>7.5</td>
</tr>
<tr>
<td>Asian American/Pacific Islander</td>
<td>9.9</td>
<td>8.8</td>
</tr>
</tbody>
</table>

*Per 100,000, age adjusted to the 2000 US standard population. †Persons of Hispanic/Latino origin may be of any race.


American Cancer Society, Surveillance Research, 2013
Figure 3. Geographic Patterns in Pancreatic Cancer Death Rates* by State and Race, US, 2005-2009.

Whites

African Americans

*Age adjusted to the 2000 US standard population. Insufficient data indicates states with fewer than 20 deaths.

Source: US mortality data, National Center for Health Statistics, Centers for Disease Control and Prevention.

American Cancer Society, Surveillance Research, 2013
Non-modifiable Factors and Medical Conditions

Family history

A number of studies have linked family history to an increased risk of pancreatic cancer. Generally, individuals with a family history of pancreatic cancer have a nearly 2-fold increased risk for developing pancreatic cancer, compared to those without such a history. The risk increases to 7- to 9-fold for individuals with at least 1 first-degree relative (a parent or sibling) with pancreatic cancer and 17- to 32-fold for individuals with 3 or more first-degree relatives with pancreatic cancer. Risk is also increased if a first-degree relative was diagnosed with pancreatic cancer before age 50.

Genetic factors

Genetic factors (factors related to gene variations or alterations) account for approximately 5% to 10% of all pancreatic cancer cases. There are several gene mutations that are associated with an increased risk of pancreatic cancer, though these are extremely rare in the general population. Mutations in the BRCA2 gene are associated with a 3- to 10-fold increased risk of pancreatic cancer and account for the highest proportion (5% to 17%) of known causes of inherited pancreatic cancer. Mutations in the CDKN2A gene, which are linked to the familial atypical multiple mole-melanoma (FAMMM) syndrome, are associated with an approximately 13- to 22-fold increased risk of pancreatic cancer. Patients with Peutz-Jeghers Syndrome (PJS), which is usually caused by STK11 mutations, have an 11% to 36% chance of developing pancreatic cancer during their lifetime. The risk among people with hereditary pancreatitis (inflammation of the pancreas) linked to PRSS1 mutations is approximately 70 times greater than that expected in the normal population, with lifetime risk of developing pancreatic cancer approximately 40% to 55%. Patients with hereditary non-polyposis colorectal cancer (HNPCC or Lynch syndrome), which is most often caused by MLH1 or MSH2 mutations, have about a 9-fold increased risk of developing pancreatic cancer. Recent studies have found that people with non-O blood groups (i.e., blood groups A, AB, and B) have a slightly increased risk of pancreatic cancer, though the mechanisms of this association are still unclear.

Chronic pancreatitis (inflammation of the pancreas)

Accumulating evidence suggests that long-standing chronic pancreatitis is a strong risk factor for pancreatic cancer, though pancreatitis may also be an early indicator of pancreatic cancer. After excluding the pancreatic cancer cases diagnosed within 2 years from chronic pancreatitis diagnosis, a review study reported a 6-fold increased risk of pancreatic cancer among patients with chronic pancreatitis. The risk is especially strong in patients with rare types of pancreatitis, such as hereditary pancreatitis and tropical pancreatitis. The lag period between pancreatitis diagnosis and pancreatic cancer onset is usually about 10 to 20 years. Despite the strong association between chronic pancreatitis and pancreatic cancer, chronic pancreatitis is uncommon; moreover, only about 4% of these patients will develop pancreatic cancer within 20 years of diagnosis.

Diabetes

About 25% of patients with pancreatic cancer have diabetes mellitus at diagnosis, and roughly another 40% have pre-diabetes (higher than normal blood glucose levels). Compared with non-diabetic individuals, patients with long-term (≥ 5 years) type-II diabetes have a 50% increased risk of pancreatic cancer. Pancreatic cancer can cause diabetes, and sometimes diabetes is an early sign of the tumor. Elevated pancreatic cancer risk has also been reported among individuals with type-1 diabetes. Recent reports also suggest that hyperglycemia (high blood glucose), abnormal glucose metabolism, and insulin resistance are associated with increased risk of pancreatic cancer.

Infection and other medical conditions

Several studies have detected an increased risk of pancreatic cancer among people with chronic infections with hepatitis B virus, hepatitis C virus, and Helicobacter pylori. Individuals with a history of cholecystectomy (surgical removal of the gallbladder) or partial gastrectomy (partial surgical removal of the stomach) have also been found to be at increased risk of developing pancreatic cancer. Other medical conditions that may increase risk include cystic fibrosis and periodontal disease.

Can Pancreatic Cancer Be Detected Early?

Early stage pancreatic cancer usually has no symptoms. When symptoms do occur, the tumor has usually spread to surrounding tissues or distant organs. Common symptoms of pancreatic cancer include mild abdominal discomfort, mid-back pain, jaundice (yellowing of the skin or whites of the eyes), and weight loss. Nausea and vomiting may occur among patients with more advanced disease. In the US, only about 15% to 20% of pancreatic cancer cases are diagnosed early enough to be eligible for surgery. To date, there is no single, reliable test for the early detection of pancreatic cancer; therefore, screening the general population is not recommended by any health agency.

Existing screening programs have been limited to research settings with a focus on detecting precancerous lesions among high-risk individuals. The most frequently tested techniques for pancreatic cancer screening include endoscopic ultrasound (EUS), helical computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic retrograde cholangiopancreatography (ERCP). Single use of EUS or various combinations of these imaging techniques are capable of detecting early pancreatic cancer or precancer in high-risk patients, such as those with chronic, hereditary, or tropical pancreatitis; Peutz-Jeghers syndrome; cystic fibrosis; or familial atypical multiple mole-melanoma. However, it remains unclear whether screening high-risk populations is effective in...
reducing pancreatic cancer mortality. Therefore, pancreatic cancer screening should currently be limited to high-risk populations within a research setting. Recent advances in understanding the molecular basis of cancer offer promise for the discovery of new methods for detecting pancreatic cancer early.

How Is Pancreatic Cancer Diagnosed?

When pancreatic cancer is suspected, patients will be asked to provide a full medical history and be given a physical exam mainly focused on the abdomen, but also of the skin and eyes for indications of jaundice (yellow coloring). Pancreatic cancer is typically diagnosed with the use of an imaging test, usually a CT scan, often with a contrast dye, given by mouth or through injection, to better outline abnormal areas. This procedure is also often used to stage the tumor, with 70% to 85% accuracy for predicting whether or not the tumor can be surgically removed. If pancreatic cancer is highly suspected but a CT scan appears normal, additional diagnostic tests, such as endoscopic ultrasound or ERCP, may be performed. The ERCP technique is especially useful in patients with bile duct tumors and endoscopic ultrasound can often detect small tumors missed by CT scan. A cancer diagnosis is typically confirmed with a biopsy – a procedure in which a small sample of the tumor is removed and viewed under a microscope. The most common type of biopsy to confirm pancreatic cancer is called a fine needle aspiration biopsy. The needle is inserted into the pancreas guided by an endoscopic ultrasound or CT scan images to obtain tissues for evaluation. However, a tissue diagnosis is not needed for patients who are scheduled for surgery. Due to the deep location of the pancreas and the medical complications of biopsy, pancreatic cancer is the least likely of all major cancers to be microscopically confirmed.

Table 2. Median Pancreatic Cancer Survival by Stage at Diagnosis

<table>
<thead>
<tr>
<th>Stage</th>
<th>Median Survival*</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>24.1 Months</td>
</tr>
<tr>
<td>IB</td>
<td>20.6 Months</td>
</tr>
<tr>
<td>IIA</td>
<td>15.4 Months</td>
</tr>
<tr>
<td>IIB</td>
<td>12.7 Months</td>
</tr>
<tr>
<td>III</td>
<td>10.6 Months</td>
</tr>
<tr>
<td>IV</td>
<td>4.5 Months</td>
</tr>
</tbody>
</table>

*Data from Bilimoria et al.

What Factors Influence Pancreatic Cancer Survival?

The prognosis (disease course and expected outcome) of pancreatic cancer is largely determined by the stage of disease at diagnosis, which is based on the tumor’s size, whether there is lymph node involvement, and the extent of spread locally and to distant organs. Table 2 presents the characteristics and median survival time for each stage of invasive pancreatic cancer. The median survival ranges from 4.5 months for the most advanced stage to 24.1 months for the earliest stage.

At present, surgery provides the only chance of prolonged survival for pancreatic cancer patients. Even for patients with a tumor that has been surgically removed (generally Stages I or II), the 5-year survival is only about 20% to 25%. Indications of a poor survival outcome include positive resection margins (cancer cells at the outer edge of the removed tissue), poor tumor differentiation (the tumor does not resemble pancreatic tissue), a large tumor size, lymph node involvement, high levels of preoperative carbohydrate (or cancer) antigen 19-9 (CA19-9), and persistently elevated levels of postoperative CA 19-9. In addition, several molecular markers have been associated with poor outcome after surgery. As these molecular markers were mainly evaluated in small studies, their value requires further validation in larger studies, and thus none have been routinely used in clinical practice.

How Is Pancreatic Cancer Treated?

Treatment

Patients with pancreatic cancer are best managed by a multidisciplinary team, including surgeons, medical and radiation oncologists, radiologists, gastroenterologists, pain management experts, nutritionists, social workers, and others. The treatment choice is largely determined by whether the tumor can be surgically removed. For those patients who are candidates for surgery (approximately 20% of all pancreatic cancer patients), the operative approaches include cephalic pancreatectoduodenectomy (the Whipple procedure), distal pancreatectomy, or total pancreatectomy, depending on the location of the tumor (see sidebar on page 31). Postoperative (adjuvant) chemotherapy either alone or in combination with radiation has been proven to improve progression-free and overall survival in both randomized controlled trials and observational studies. The role of radiation therapy by itself in the adjuvant setting remains unclear. Treatment with chemotherapy or chemoradiotherapy prior to surgery (neoadjuvant) is an emerging strategy. The goal of neoadjuvant treatment is to increase the ability to successfully remove all of the tumor. However, there is no evidence that neoadjuvant therapy is superior to adjuvant therapy, especially among those patients who clearly have resectable disease. For this reason,
neoadjuvant treatment is considered more relevant for patients with locally advanced or borderline resectable disease.\textsuperscript{97–99}

The treatment for patients with advanced disease focuses on managing symptoms and relieving pain and suffering (palliative care). Treatment options include chemotherapy alone or in combination with radiation. The combination of 5-FU, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) can help prolong life in patients with advanced disease, though many patients are too ill to tolerate this regimen. Other treatment options include gemcitabine alone or in combination with a platinum agent, erlotinib (Tarceva), or fluoropyrimidine.\textsuperscript{82}

Supportive care
Given the poor survival and persistent symptoms experienced by many pancreatic cancer patients who do not respond to treatment, care focusing on relieving and preventing suffering represents an important aspect of managing this disease. Palliative care should be offered at the initiation of any treatment regimen in order to relieve symptoms and side effects, which include pain, bile duct or gastric outlet obstruction, and loss of appetite. Palliative efforts may also include psychological support to relieve patients’ stresses associated with pancreatic cancer diagnosis and treatment.

Opioid analgesics (morphine and similar drugs) are often needed to help reduce pain. Radiation may be given to help relieve pain from locally advanced disease. Another pain management approach is nerve block, whereby a pain specialist injects either an anesthetic or a medication to block or destroy the nerves. For example, abdominal pain can sometimes be treated effectively by endoscopic ultrasound or CT guided celiac plexus block.

If the tumor is blocking the bile duct, a stent (a thin tube) can be placed to relieve the blockage using nonsurgical approaches, such as ERCP and percutaneous transhepatic cholangiogram (PTC). If a patient develops gastric-outlet obstruction, treatment may include duodenal wall stents or PEG (percutaneous endoscopic gastrostomy) placement for decompression. Sometimes, a patient may need surgery to create a bypass (biliary bypass or gastric bypass) to manage obstructive jaundice and gastric outlet obstruction.

If the pancreas is not working well or has been partially or entirely removed, a special diet and specially prescribed enzymes may help the patient’s digestion. Meeting with a nutritionist is also often very helpful for patients who are losing weight and have a poor appetite because of their disease.

What Is the American Cancer Society Doing about Pancreatic Cancer?

Research
The American Cancer Society, through its Extramural Grants program, funds individual investigators in medical schools, universities, research institutes, and hospitals throughout the United States. Currently, this program is funding $8,077,500 in pancreatic cancer research through 32 research grants. Ongoing research includes:

- Identifying new avenues of early detection and treatment through better understanding of the biological mechanisms of pancreatic cancer development, progression, and metastasis
- Determining the optimal sequencing strategy for pancreatic cancer treatment through mathematical decision analysis
The American Cancer Society Cancer Action Network (ACS CAN) is part of a large international Pancreatic Cancer Cohort (PanScan), which aims to identify genetic factors, environmental exposures, and gene-environment interactions that contribute to the development of pancreatic cancer. To date, PanScan researchers have discovered four novel interactions that contribute to the development of pancreatic cancer. For example, researchers from the surveillance research program monitor trends in pancreatic cancer incidence and mortality, and recently published a study showing that socioeconomic disparities in pancreatic cancer death rates widened among working-age US populations during 1993-2007. Using data collected in the Society’s Cancer Prevention Study II (CPS-II), Society epidemiologists have also examined the relationship between pancreatic cancer death and various factors, including alcohol consumption, carbohydrate intake, aspirin use, and reproductive patterns. In addition, the CPS-II Nutrition Cohort is part of a large international Pancreatic Cancer Cohort Consortium (PanScan), which aims to identify genetic factors, environmental exposures, and gene-environment interactions that contribute to the development of pancreatic cancer. To date, PanScan researchers have discovered four novel regions in the genome associated with risk for pancreatic cancer. In addition, many other epidemiological studies on environmental risk factors (including lifestyle factors) have been published.

Advocacy

The American Cancer Society Cancer Action Network (ACS CAN), the nonprofit nonpartisan advocacy affiliate of the American Cancer Society, recognizes that cancer research is the engine behind our ongoing progress in the fight against cancer. Research offers hope to the millions of people who face cancer – for better treatments, for more opportunities to prevent and detect the disease early, and for improved quality of life for those already diagnosed. The National Cancer Institute (NCI) – one of the 27 institutes and centers that comprise the National Institutes of Health (NIH) – is the foundation of the nation’s cancer research efforts. As a federal agency, NCI-funded research has played a role in every major advance in the fight against cancer over the past 70 years. That’s why it is so important that the NCI continues to receive the government investment that it needs to support lifesaving research projects. Funding for pancreatic cancer research at NCI has increased from $73 million in 2007 to $100 million in 2011. Billions of dollars exist in the federal budget for medical research purposes, and ACS CAN is leading the effort to lobby our government for the crucial funds necessary for the clinical research that could lead to the prevention, early detection, and effective treatment of pancreatic cancer.

Resources outside the American Cancer Society

- National Cancer Institute: cancer.gov/cancertopics/types/pancreatic/
- Pancreatic Cancer Action Network: pancan.org/
- The Lustgarten Foundation: lustgarten.org/
- Hirshberg Foundation for Pancreatic Cancer Research: pancreatic.org/
- National Pancreas Foundation: pancreasfoundation.org/
- Pancreatica Initiative: pancreatica.org/

References


